References
E.L. Diamond, L. Dagna, D.M. Hyman, G. Cavalli, F. Janku, J. Estrada-Veras, M. Ferrarini, O. Abdel-Wahab, M.L. Heaney, P.J. Scheel, N.K. Feeley, E. Ferrero, K.L. McClain, A. Vaglio, T. Colby, L. Arnaud, J. Haroche, Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124, 483–492 (2014)
F. Cohen Aubart, J.F. Emile, F. Carrat, F. Charlotte, N. Benameur, J. Donadieu, P. Maksud, A. Idbaih, S. Barete, K. Hoang-Xuan, Z. Amoura, J. Haroche, Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood 130, 1377–1380 (2017)
A. Zaidi, U. Gautam, R. Srinivasan, A. Bal, G. Prakash, A. Sood, Challenging diagnosis of two neoplasms, Langerhans cell histiocytosis and papillary thyroid carcinoma from fine needle aspiration of the thyroid by cell block immunocytochemistry and molecular testing for BRAFV600E mutation. Cytopathology. (2020). https://doi.org/10.1111/cyt.12816
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the patient.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Klain, M., Schlumberger, M. & Cuocolo, A. Concurrent BRAF V600E mutated papillary thyroid carcinoma and Erdheim–Chester disease. Endocrine 70, 655–656 (2020). https://doi.org/10.1007/s12020-020-02317-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-020-02317-1